AMRI is reducing its US workforce 10 per cent and halting operations in one R&D lab at its facility in Rensselaer, New York as “softness” in the domestic market continues beyond its expectations.
US biotech Genzyme will pay $175m and cease some manufacturing operations at its facility in Allston, Massachusetts under final terms of Food and Drug Administration (FDA) consent decree.
The Indian Government plans to help medium sized pharmaceutical firms meet World Health Organisation (WHO) manufacturing plant standards with a new subsidy scheme.
US CMO Contract Pharmaceuticals (CPL) to close Buffalo plant by the end of 2011 on weak demand it attributes to pharmaceutical industry outsourcing cuts in downturn.
An increase in demand for rayon fabric in China has led to higher prices for microcrystalline cellulose, an excipient for pharmaceuticals and a stabilizer for foods, drinks and personal care products.
Pfizer plans to close eight manufacturing sites and reduce operations at a further six by the end of 2015, leading to 6,000 job losses, as part of its reorganisation after acquiring Wyeth.
Beike Biotechnology has opened a stem cell storage and processing facility at the 20,000 sq m regenerative medicine base in China, furthering the nation’s development in the field.
DSM Biologics says successful XD tech expansion paves way for smaller bioreactors that lowers cost of production facilities and, ultimately, of bio-drug manufacture.
Albany Molecular Research (AMRI) says Q1 decline is due to “soft” demand for contract manufacturing services and trial materials, but is still confident of full-year growth.
Cambrex has posted a 55 per cent drop in operating profit in the first quarter, underpinned by the timing of orders, disruption to a customer’s supply chain and lower pricing of certain generic APIs.
The Office of the United States Trade Representative (USTR) has expressed particular concern about the proliferation of counterfeit drugs in countries including Brazil, China, India, Indonesia and Russia.
The US FDA says Teva Pharmaceutical Industries’ plan to fix cGMP violations observed at its plant in Irving, California “lack sufficient corrective actions.”
US firm SAFC plans to turn its dry powder culture media manufacturing plant in Lenexa, Kansas into a “centre of excellence” with $6.3m (€4.7m) capacity expansion.
The USP and FDA must work to identify counterfeited or intentionally adulterated products before they enter the healthcare system by collaborating on the modification of monographs, according to Margaret Hamburg.
Capacity at Blu Pharmaceutical’s recently acquired solid dosage production plant in Puerto Rico is set to expand considerable over the next three years according to company president Bill Luster.
A project bringing together researchers from academia and pharma companies, including GSK and AZ, has received a £709,000 ($1.09m) grant to create crystals using continuous flow production.
in-PharmaTechnologist presents exclusive interactive maps of pharma manufacturing facilities in India, detailing the number of bulk drug and formulation facilities in each region of the country.
The US Food and Drug Administration (FDA) has issued Apotex with another warning letter about cGMP violations at two plants explaining the firm’s response to previous warnings “is inadequate and lacks sufficient corrective actions.”
Archimica has entered into an exclusive distribution agreement with a Merck KGaA subsidiary to provide building blocks and special reagents for organic synthesis.
Winsunny Pharma has exclusively licensed NMT’s HGCP technology, which produces APIs in low micron and nano-sized range, to manufacture a hyperlipidemia-controlling drug in China.
Sanofi-Aventis says French manufacturing operations will focus on vaccine and biotech drugs, unveiling €150m ($202m) plan to shift emphasis away from synthetic chemistry-based production.
The WHO has published its views on the production of starting materials in draft guidance which details recommendations to ensure product quality while keeping costs down.
The European Medicines Agency (EMA) has recommended a recall of Acino’s generic Plavix (clopidogrel bisulfate) because of alleged failings in GMP at the API production facility.
The UK budget was “a missed opportunity” to encourage manufacturing, according to UK Chemical Industries Association (CIA), but was free from unexpected tax increases.
Contract manufacturing organization (CMO) ScinoPharm says strong anticancer API sales and growing demand in Europe and Asia were key to record performance in 2009.
The IPEA's issuance of good manufacturing practice (GMP) “certification” is mark of manufacturing quality, says US specialty chemicals supplier W R Grace & Co.
GSK has confirmed that material from the PCV1 virus has been detected in Rotarix and, although there is no evidence of a safety risk, the FDA has recommended use is temporarily suspended.
Dr Reddy’s has made a “significant investment” in an mPEG alcohol production facility in Mexico to strengthen its presence in a sector it believes is on the rise.
The Botswanan government is seeking to initiate local pharma manufacturing, which would lower drug prices, by entering into public-private partnerships (PPP), according to a report by F&S.
CEO Steffen Mittwich updates in-PharmaTechnologist on Atacama Labs' pneumatic dry granulation (PDG) API processing tech, its deal with German CMO Excella and future development plans.
Ireland must become an R&D hub as well as a drug manufacturing destination to prosper in the increasingly competitive global pharmaceutical market, says industry body PharmaChemical Ireland (PCI).
Prosonix’ new UMAX particle engineering technology is set to “revolutionise” the field of respiratory medicines, according to company CEO David Hipkiss.
Drug researchers will have greater access to some top selling molecules, including currently patented compounds atorvastatin, sildenafil and celecoxib, thanks to Sigma Aldrich’s new bioactives deal with US drug major Pfizer.
The Chinese government is supporting a $100m (€73m) project to build a contract biologics production facility in Beijing, which, by some measures, would be the largest in Asia.
Pharmadule AB is creating a complete modular biologics production facility, which will be 80 per cent completed in its workshop before delivery, to Lithuania-based Silcor Biotech by 2011.
Glycos Biotechnologies has produced lactic acid in a pilot plant using its sustainable technique, successfully scaling up from a laboratory setting to provide an alternate source for the chiral synthon.
Cambridge Major Laboratories (CML), Avantium, Xcelience and Beckloff have formed a consortium to offer tailored, client-focused CMC packages which are particularly suited to atypical compounds.
Wacker Chemie AG has expanded its biologics production facility, adding GMP manufacturing capacity and a process development building in response to customer demand.
